DIABETES THERAPY IN CYSTIC FIBROSIS SUBJECTS

囊性纤维化患者的糖尿病治疗

• 批准号: 7604942
• 负责人: Theodore Geh-Lu Liou
• 金额: $ 0.27万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604942
• 关键词: Adult; Body Composition; Body Weight; Chronic; Clinical; Computer Retrieval of Information on Scientific Projects Database; Cystic Fibrosis; Diabetes Mellitus; Doctor of Medicine; Fasting; Funding; Glucose; Grant; Hyperglycemia; Institution; Insulin; Intervention Trial; Lead; Minnesota; Morbidity - disease rate; Muscle; Oral; Placebo Control; Placebos; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Universities; cystic fibrosis patients; diabetes mellitus therapy; improved; mortality; prospective; pulmonary function; repaglinide

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cystic Fibrosis Related Diabetes (CFRD) is present in approximately 40% of adult patients with cystic fibrosis and is associated with increased morbidity and mortality. Patients with CFRD are not routinely treated with exogenous insulin when their fasting glucose levels are normal. We hypothesize that chronic treatment with either insulin or an oral stimulator of endogenous insulin will lead to improved muscle mass and clinical status in adult CF patients with CFRD without fasting hyperglycemia. This is a multi-center, prospective, placebo-controlled intervention trial coordinated by Antoinette Moran, M.D. at the University of Minnesota. Subjects will be treated for 12 months with either insulin or repaglinide or an oral placebo. The effects of these agents on muscle mass, body weight, body composition and pulmonary function will be evaluated.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 囊性纤维化相关糖尿病（CFRD）存在于约40%的囊性纤维化成人患者中，并与发病率和死亡率增加相关。当空腹血糖水平正常时，CFRD患者不常规接受外源性胰岛素治疗。我们假设，长期使用胰岛素或口服内源性胰岛素刺激剂治疗，可改善无空腹高血糖的CFRD成人CF患者的肌肉质量和临床状态。这是一项多中心、前瞻性、安慰剂对照干预试验，由Antoinette Moran，M.D.协调。在明尼苏达大学。受试者将接受胰岛素或瑞格列奈或口服安慰剂治疗12个月。将评价这些药物对肌肉质量、体重、身体组成和肺功能的影响。